DKK1,507.50
1.52% day before yesterday
Copenhagen, Dec 27, 04:59 pm CET
ISIN
DK0010272202
Symbol
GMAB
Sector

Genmab A/S Stock price

DKK1,507.50
+19.50 1.31% 1M
-271.00 15.24% 6M
-647.50 30.05% YTD
-630.50 29.49% 1Y
-1,088.50 41.93% 3Y
+19.50 1.31% 5Y
+1,148.50 319.92% 10Y
Copenhagen, Closing price Fri, Dec 27 2024
+22.50 1.52%
ISIN
DK0010272202
Symbol
GMAB
Sector

Key metrics

Market capitalization DKK95.76b
Enterprise Value DKK79.43b
P/E (TTM) P/E ratio 20.97
EV/FCF (TTM) EV/FCF 12.09
EV/Sales (TTM) EV/Sales 4.02
P/S ratio (TTM) P/S ratio 4.85
P/B ratio (TTM) P/B ratio 3.00
Revenue growth (TTM) Revenue growth 16.10%
Revenue (TTM) Revenue DKK19.76b
EBIT (operating result TTM) EBIT DKK6.41b
Free Cash Flow (TTM) Free Cash Flow DKK6.57b
Cash position DKK17.32b
EPS (TTM) EPS DKK71.88
P/E forward 17.57
P/S forward 4.51
EV/Sales forward 3.74
Show more

Is Genmab A/S a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Genmab A/S Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Genmab A/S forecast:

17x Buy
61%
10x Hold
36%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a Genmab A/S forecast:

Buy
61%
Hold
36%
Sell
4%

Financial data from Genmab A/S

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
19,763 19,763
16% 16%
100%
- Direct Costs 774 774
-
4%
18,989 18,989
-
96%
- Selling and Administrative Expenses 3,550 3,550
8% 8%
18%
- Research and Development Expense 9,033 9,033
23% 23%
46%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 6,406 6,406
1% 1%
32%
Net Profit 4,639 4,639
8% 8%
23%

In millions DKK.

Don't miss a Thing! We will send you all news about Genmab A/S directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,204
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today